Drug Type siRNA |
Synonyms pan-KRAS centyrin-siRNA conjugates, ABX-300 |
Target |
Action inhibitors |
Mechanism KRAS inhibitors(GTPase KRas inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immune System Diseases | Preclinical | United States | 11 Dec 2018 | |
| KRAS mutation-related tumors | Preclinical | United States | 11 Dec 2018 | |
| Muscular Diseases | Preclinical | United States | 11 Dec 2018 |





